Milton C. Ault III net worth and biography

Milton Ault III Biography and Net Worth

Major Shareholder of Alzamend Neuro

Milton C. (Todd) Ault III founded our company and has served as our Chairman of the Board since inception and as our Executive Chairman since November 2018. As of June 10, 2021, Mr. Ault serves as our Chairman Emeritus. Mr. Ault is a seasoned business professional and entrepreneur who has spent more than 27 years identifying value in various financial markets including equities, fixed income, commodities and real estate. In March 2017, Mr. Ault was appointed Executive Chairman of the Board of Ault Global, in December 2017, Mr. Ault was appointed Chief Executive Officer of Ault Global and, on January 12, 2021, Mr. Ault resumed his title of Executive Chairman. Mr. Ault has served as Chairman of Ault & Company, a holding company since December 2015, and as Chairman of Avalanche International Corp., a publicly traded company (“Avalanche”), since September 2014. Since January 2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Mr. Ault has consulted with many publicly traded and privately held companies, which range from development stage to mature businesses, providing each of them the benefit of his diversified experience.

What is Milton C. Ault III's net worth?: The estimated net worth of Milton C. Ault III is at least $205.27 thousand as of November 28th, 2025. Mr. Ault III owns 96,369 shares of Alzamend Neuro stock worth more than $205,266 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Ault III may own. Learn More about Milton C. Ault III's net worth.
How old is Milton C. Ault III?: Mr. Ault III is currently 54 years old. There are 4 older executives and no younger executives at Alzamend Neuro. The oldest executive at Alzamend Neuro is Mr. Kenneth S. Cragun CPA, Senior Vice President of Finance, who is 63 years old. Learn More on Milton C. Ault III's age.
How do I contact Milton C. Ault III?: The corporate mailing address for Mr. Ault III and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6303. Learn More on Milton C. Ault III's contact information.
Has Milton C. Ault III been buying or selling shares of Alzamend Neuro?: In the last ninety days, Milton C. Ault III has sold $935,245.77 in shares of Alzamend Neuro stock. Most recently, Milton C. Ault III sold 20,397 shares of the business's stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $2.32, for a transaction totalling $47,321.04. Following the completion of the sale, the director now directly owns 8,260 shares of the company's stock, valued at $19,163.20. Learn More on Milton C. Ault III's trading history.
Who are Alzamend Neuro's active insiders?: Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.
Are insiders buying or selling shares of Alzamend Neuro?: During the last year, Alzamend Neuro insiders bought shares 4 times. They purchased a total of 1,491 shares worth more than $13,054.32. During the last year, insiders at the sold shares 23 times. They sold a total of 904,662 shares worth more than $2,212,048.49. The most recent insider tranaction occured on October, 23rd when Director Lynne Fahey Mcgrath sold 30 shares worth more than $68.70. Insiders at Alzamend Neuro own 30.2% of the company. Learn More about insider trades at Alzamend Neuro.
Information on this page was last updated on 10/23/2025.

Milton C. Ault III Insider Trading History at Alzamend Neuro

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/9/2025	Sell	20,397	$2.32	$47,321.04	8,260
10/8/2025	Sell	101,394	$2.44	$247,401.36	28,657
10/7/2025	Sell	57,379	$2.49	$142,873.71	68,848
10/6/2025	Sell	82,033	$2.45	$200,980.85	26,227
10/3/2025	Sell	65,903	$2.44	$160,803.32	8,260
10/2/2025	Sell	20,686	$2.39	$49,439.54	74,163
10/1/2025	Sell	36,777	$2.35	$86,425.95	94,849
9/30/2025	Sell	3,566	$2.33	$8,308.78	31,626
9/29/2025	Sell	38,324	$2.31	$88,528.44	35,192
9/26/2025	Sell	37,738	$2.31	$87,174.78	73,516
9/25/2025	Sell	14,628	$2.31	$33,790.68	11,254
9/24/2025	Sell	39,140	$2.31	$90,413.40	25,882
9/23/2025	Sell	43,238	$2.38	$102,906.44	65,022
9/19/2025	Sell	77,009	$2.35	$180,971.15	8,260
9/18/2025	Sell	20,870	$2.47	$51,548.90	85,269
9/17/2025	Sell	2,121	$2.45	$5,196.45	106,139
7/31/2025	Sell	100,000	$2.22	$222,000.00	8,260
7/30/2025	Sell	29,449	$2.51	$73,916.99	108,260
7/28/2025	Sell	8,311	$2.68	$22,273.48	37,709
7/25/2025	Sell	36,532	$2.90	$105,942.80	46,020
7/24/2025	Sell	9,621	$2.93	$28,189.53	82,552
7/23/2025	Sell	59,516	$2.95	$175,572.20	92,173
3/18/2025	Buy	555	$8.64	$4,795.20	9,152
3/12/2025	Buy	11	$6.12	$67.32	8,596
8/6/2024	Buy	8	$24.75	$198.00	8,585
7/31/2024	Buy	2	$33.66	$67.32	8,577
4/19/2024	Buy	11	$62.10	$683.10	8,574
4/1/2024	Buy	3	$81.90	$245.70	8,563
1/5/2024	Buy	55	$91.80	$5,049.00	8,537
12/26/2023	Buy	5	$81.00	$405.00	289
12/22/2023	Buy	2	$82.80	$165.60	1,854
5/24/2023	Buy	13	$796.50	$10,354.50	283
3/16/2023	Buy	2	$675.00	$1,350.00	8,188
2/15/2023	Buy	0	$810.00	$0.00	8,185
12/27/2022	Buy	0	$796.50	$0.00	8,182
11/18/2022	Buy	0	$1,741.50	$0.00	8,176
10/31/2022	Buy	4	$1,606.50	$6,426.00	7,483
10/12/2022	Buy	1	$1,660.50	$1,660.50	7,479
10/6/2022	Buy	0	$1,930.50	$0.00	7,477
9/29/2022	Buy	2	$1,606.50	$3,213.00	7,476
8/25/2022	Buy	3	$1,296.00	$3,888.00	7,413
8/22/2022	Buy	26	$1,309.50	$34,047.00	7,409
8/15/2022	Buy	10	$1,431.00	$14,310.00	7,371
8/3/2022	Buy	1	$1,282.50	$1,282.50	7,360
7/27/2022	Buy	4	$1,174.50	$4,698.00	7,359
7/22/2022	Buy	1	$1,228.50	$1,228.50	7,354
7/18/2022	Buy	7	$1,323.00	$9,261.00	7,353
6/29/2022	Buy	7	$1,188.00	$8,316.00	7,345
6/17/2022	Buy	7	$1,188.00	$8,316.00	7,338
6/14/2022	Buy	7	$1,147.50	$8,032.50	7,323
6/7/2022	Buy	1	$1,269.00	$1,269.00	7,310
6/2/2022	Buy	5	$1,296.00	$6,480.00	7,308
5/26/2022	Buy	7	$1,228.50	$8,599.50	7,293
5/24/2022	Buy	11	$1,201.50	$13,216.50	7,286
5/17/2022	Buy	17	$1,323.00	$22,491.00	7,270
5/12/2022	Buy	18	$1,147.50	$20,655.00	7,253
5/5/2022	Buy	74	$1,444.50	$106,893.00	240
4/26/2022	Buy	1,975	$2,025.00	$3,999,375.00	7,160
4/22/2022	Buy	55	$1,269.00	$69,795.00	166
4/11/2022	Buy	37	$1,525.50	$56,443.50	111
3/18/2022	Buy	74	$1,485.00	$109,890.00
2/24/2022	Buy	16	$1,552.50	$24,840.00
1/27/2022	Buy	1	$1,890.00	$1,890.00
1/24/2022	Buy	3	$1,741.50	$5,224.50
1/18/2022	Buy	5	$2,241.00	$11,205.00
1/14/2022	Buy	2	$2,416.50	$4,833.00
1/7/2022	Buy	2	$2,605.50	$5,211.00
1/5/2022	Buy	1	$2,673.00	$2,673.00
12/23/2021	Buy	1	$2,835.00	$2,835.00
12/20/2021	Buy	18	$2,848.50	$51,273.00
12/17/2021	Buy	9	$3,348.00	$30,132.00
11/30/2021	Buy	3	$3,064.50	$9,193.50
11/22/2021	Buy	11	$2,565.00	$28,215.00
11/8/2021	Buy	107	$3,469.50	$371,236.50
9/14/2021	Buy	3	$3,645.00	$10,935.00	111
8/27/2021	Buy	4	$3,915.00	$15,660.00
8/17/2021	Buy	2	$4,441.50	$8,883.00
8/12/2021	Buy	2	$5,224.50	$10,449.00
8/9/2021	Buy	0	$5,467.50	$0.00
8/6/2021	Buy	2	$5,494.50	$10,989.00
8/4/2021	Buy	0	$5,805.00	$0.00
8/2/2021	Buy	1	$6,156.00	$6,156.00
7/30/2021	Buy	991	$2,038.50	$2,020,153.50
7/26/2021	Buy	2	$6,669.00	$13,338.00
7/23/2021	Buy	3	$7,776.00	$23,328.00
7/19/2021	Buy	2	$7,303.50	$14,607.00
7/16/2021	Buy	0	$8,410.50	$0.00
7/14/2021	Buy	3	$9,099.00	$27,297.00
7/12/2021	Buy	6	$8,302.50	$49,815.00
7/8/2021	Buy	1	$8,208.00	$8,208.00
7/6/2021	Buy	5	$9,544.50	$47,722.50
6/28/2021	Buy	6	$12,973.50	$77,841.00
6/25/2021	Buy	10	$11,866.50	$118,665.00
6/22/2021	Buy	54	$12,541.50	$677,241.00

Milton C. Ault III Buying and Selling Activity at Alzamend Neuro

Alzamend Neuro Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $2.15

$2.04

$2.17

50 Day Range

MA: $2.33

$1.96

$2.61

2 Week Range

Now: $2.15

$1.88

$12.06

Volume

23,487 shs

Average Volume

96,172 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Milton Ault III Biography and Net Worth

What is Milton C. Ault III's net worth?

How old is Milton C. Ault III?

How do I contact Milton C. Ault III?

Has Milton C. Ault III been buying or selling shares of Alzamend Neuro?

Who are Alzamend Neuro's active insiders?

Are insiders buying or selling shares of Alzamend Neuro?

Milton C. Ault III Insider Trading History at Alzamend Neuro

Milton C. Ault III Buying and Selling Activity at Alzamend Neuro

Alzamend Neuro Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta